CareRx Q4 EPS Tops Estimates by $0.25, Revenue Misses by $26.23M
CareRx reported Q4 EPS of $0.26 versus estimates of $0.01 while revenue of $69.97M fell short of the $96.2M forecast. The stock trades at a price-to-sales ratio of 0.65, enterprise value-to-sales of 0.83 and EV/operating cash flow of 10.26, with a debt-to-equity of 0.94.
1. Q4 Financial Performance
CareRx reported earnings per share of $0.26 compared to an estimated $0.01 while revenue totaled $69.97 million, missing the $96.2 million forecast by $26.23 million.
2. Valuation Metrics
The company’s price-to-sales ratio stands at 0.65 with an enterprise value-to-sales ratio of 0.83. Its EV to operating cash flow ratio is 10.26 and earnings yield is 0.04%.
3. Financial Health Indicators
CareRx maintains a debt-to-equity ratio of 0.94 and a current ratio of 1.13, reflecting a balanced leverage position and adequate short-term liquidity.